|
|
||||||||

*
Department of Neurology and Neurosurgery, McGill University, Montréal Neurological Institute, Montréal, Québec, Canada; and
Neuroimmunology Branch, National Institutes of Health, Bethesda, MD 20892
| Abstract |
|---|
|
|
|---|
| Introduction |
|---|
|
|
|---|
/ß T cells and

T cells as well as macrophages and microglia (5, 6, 7, 8). Whether or
how each of these cell types actually damage myelin and OLs is still
largely unknown. Although it has not yet been demonstrated that OLs in situ express either MHC class I or class II molecules by conventional immunohistochemical techniques, in vitro OLs, both human and murine, have been shown to express MHC class I molecules (9, 10, 11, 12). This finding raises the question as to whether these cells could be vulnerable to MHC class I-restricted CD8 T cell-mediated cytotoxicity. Human OLs are susceptible to lysis mediated by cytotoxic cells that are directed at MHC class I alloantigens generated and activated in a mixed lymphocyte reaction (13).
Myelin-reactive MHC class I-restricted human CD8 T cells can be generated in vitro (14). Tsuchida et al. used a computer algorithm to predict the peptide sequences, which can form stable complexes with HLA-A2, and confirmed that most were stable in in vitro experiments (14). One of these peptides was myelin basic protein (MBP) peptide region 110118, which is coded in exon 3 of the MBP (15). This exon is present in all known forms of MBP (15). Tsuchida et al. were able to generate CD8-specific cytotoxic T cell lines recognizing MBP peptide 110118 from the PBMC of 1 of 10 healthy donors and 1 of 9 MS patients. These lines showed MHC class I-restricted cytotoxicity when tested using a transformed B cell line (HMy2.C1R) transfected with HLA-A2 pulsed with peptide as a target. HLA-A1-transfected cells were used as controls.
The purpose of the current study was to generate MBP peptide-specific CD8 T cell lines from HLA-A2 MS patients and normal donors, using the same MBP peptide (110118) that was previously described by Tsuchida et al., and to assess the capacity of these cells to induce cytotoxicity to MHC class I- histocompatible OLs maintained in dissociated cell culture in the absence of any exogenous MBP.
| Materials and Methods |
|---|
|
|
|---|
Venous blood samples were obtained either from normal donors or from patients with the relapsing-remitting form of MS that were currently in remission. The donors were all tissue-typed using serologic techniques at the Tissue Typing Laboratory of the Royal Victoria Hospital (Montréal, Canada) and selected on the basis of HLA-A2 positive status.
CD8 T cell lines
CD8 T cells reactive to the 110118 MBP peptide (SLSRFSWGA), (Department of Biochemistry, Queens University, Kingston, Canada) were generated using a technique similar to that used in the study reported by Tsuchida et al. (14). A whole mononuclear cell (MNC) fraction was initially isolated on a Ficoll-Hypaque density gradient. Purified CD8 T cells were then obtained using magnetic beads coated with anti-CD8 mAb (Dynal, Great Neck, NY) according to the manufacturers protocol. After washing, the CD8 T cells were suspended in culture medium, DMEM (Life Technologies, Burlington, Ontario) with 10% autologous serum containing streptomycin (50 µg/ml) and penicillin (50 U/ml) (Life Technologies) at 106 cells/ml. Irradiated (3000 R), autologous MNC feeder cells pulsed with MBP peptide (10 µg/ml) were added. On day 3, 5 U/ml of IL-2 (Genzyme, Cambridge, MA) was added to the CD8 T cell cultures. At 1 wk from the time of the initial culture and for each subsequent week, the CD8 T cells were provided with fresh irradiated autologous feeder cells and pulsed with peptide. On day 2 after every peptide stimulation, 5 U/ml of IL-2 was added to CD8 T cell cultures. The peptide and MHC class I specificity of the cell lines were assessed based on a chromium release assay (Na251CrO4), as described below.
Target cell lines
HMy2.C1R cells, which comprise the transformed B cell line HMy2.C1R transfected with HLA-A2 or HLA-A3, were prepared and maintained as previously described (14). OLs were prepared from human adult temporal lobe tissue resected as a surgical treatment of intractable epilepsy, as previously described (16). Our procedure involves initial trypsinization of the CNS tissue, passage through mesh, and centrifugation on a 30% Percoll gradient. The initial mixture of dissociated glial cells was suspended in MEM (Life Technologies) with 5% FCS (Medicorp, Montréal, Québec), streptomycin (50 µg/ml), and penicillin (50 U/ml) and cultured for 48 h in culture flasks. This step provides a means of separating adherent cells, such as microglia and astrocytes, from nonadherent cells, such as OLs. The nonadherent OL fraction was plated into poly-L-lysine-coated wells of 96-well microtiter plates at 5 x 104 cells/well. The HLA type of OL was determined by HLA-typing that was performed on MNC derived from the blood of the individual whose brain tissue was used as a source of OLs.
Cytotoxicity assays
To assess cytotoxic potential and the MHC class I restriction of the MBP peptide-reactive CD8 T cell lines we used, HLA-A2- or HLA-A3-transfected HMy2.C1R cell lines as targets. These cells were labeled with Na251CrO4 (5 HCi/ml) for 1 h and then washed to remove the label. The cells were pulsed either with MBP peptide 110118 or with influenza virus peptide 5866 (also presented in an HLA-A2-restricted manner) (17), or they were not pulsed with any peptide. Target cells (5 x 103) were plated in each well of a 96-well microtiter plate. CD8 T cells (5 x 104 per well) were added.
For human OL cytotoxicity assays, we labeled OLs with Na251CrO4 (1 µCi/well) overnight and washed them the next day. CD8 T cells (5 x 105) were added to each microwell to obtain a 10:1 E:T ratio. For both the transfected HMy2.C1R cells and the OL cytotoxicity studies, the supernatant was collected after 5 h to determine 51Cr release. The total 51Cr release was assessed after cell treatment with 1% Triton X-100. Spontaneous release was determined from microwells containing only target cells. 51Cr release was read in a gamma counter (LKB Wallac, Gaithersburg, MD). The percentage of specific release was calculated as: ([induced release - spontaneous release]/[total release - spontaneous release]) x 100%. All assays were performed in triplicate.
To establish that OL-directed cytotoxicity was MHC class I restricted, we added pan-MHC class I-blocking Ab (W6/32) or control isotype Ab to some of the cultures.
Immunocytochemistry
The purity of OL cultures was assessed by immunostaining those cells recovered from microtiter wells with anti-galactocerebroside Ab (O1) (a gift from Dr. Wee Yong, University of Calgary, Calgary, Canada) followed by goat anti-human Ig and FACS analysis. The expression of MHC class I on OLs was determined by preconjugated anti-MHC class I Ab (Serotec, Oxford, U.K.) staining and FACS analysis. Anti-keyhole limpet hemocyanin isotype-matched mAbs were used as controls. The purity of CD8 T cell cultures was assessed by double staining lymphocytes with phycoerythrin (PE)-conjugated anti-CD4 and FITC-conjugated anti-CD8 Ab (Becton Dickinson, Mountain View, CA) followed by FACS analysis.
| Results |
|---|
|
|
|---|
|
5 to 8 x 106
CD8 T cells per donor, which limited the number of experiments we were
able to do with one line.
|
|
|
|
|
| Discussion |
|---|
|
|
|---|
The studies using OLs as targets indicate that MHC class I-restricted lysis could be obtained in the absence of exogenous MBP peptide. Although the overall level of 51Cr release by OLs was lower than that displayed by HLA-A2-transfected cells, the cytotoxicity was dependent upon the expression of the appropriate MHC class I molecule and inhibited by the anti-MHC class I Ab. The lower extent of 51Cr could reflect a number of variables. The OLs are fully differentiated, nondividing cells compared with the proliferating HMy2.C1R cells. The transfected HMy2.C1R cells pulsed with peptide likely differ from the OLs with regard to the amount of MBP peptide present in the MHC class I groove. For the OLs, peptide presentation could result from endogenous Ag processing. The OLs also express MHC class I molecules other than HLA-A2, and their peptide grooves are probably occupied by multiple, different peptides. We did not have methods available to demonstrate whether the MBP peptide was present in the MHC class I groove of either OL or HLA-A2-transfected HMy2.C1R cells. Recent data indicate that the presentation of one molecule of Ag in the appropriate peptide groove is sufficient for T cell recognition and response (18).
The CD8 T cell-mediated injury of myelin targets has been postulated to contribute to tissue injury in a number of model and human diseases. Jewtoukoff et al. previously described a murine CD8 T cell clone specifically cytotoxic for OL but lacking in MHC class I restriction (19). In experimental autoimmune encephalomyelitis, depletion of CD8 T cells results in prolonged disease, but there was no mention of the extent of overall tissue injury (20, 21). In Theilers virus encephalomyelitis model, susceptibility to demyelination is mapped within the MHC class I region (22). In human T cell lymphotropic virus type I myelopathy, a high frequency of CD8 T viral peptide-reactive T cells is found in blood and at lesion sites (23), but whether these cells can damage OLs is unknown.
The results of the present study expand the range of effector cells
that are present in the inflammatory MS lesions and could mediate
actual tissue injury. MBP-reactive CD4 T cells expressing CD56 can
induce lysis of an array of cell targets in a non-MHC,
non-Ag-restricted manner (24). 
T cells can directly induce lysis
of human OLs, although the required ligand is not yet identified (25).
An array of soluble molecules, including TNF and nitric oxide, which
can be produced by inflammatory cells or endogenous microglia, can also
be cytotoxic to OLs (26). Our studies with lectin-dependent CD8 and CD4
T cell-mediated lysis of OLs indicate that non-TNF- and
non-Fas-dependent mechanisms mediate most of OL injury, suggesting that
classical perforin-mediated injury would likely be the underlying
mechanism of injury (27, 28). In none of these studies do we find a
correlation between susceptibility to lysis and the HLA phenotype of
the OLs. Understanding the events that link initial inflammation to
ultimate tissue injury in MS will hopefully provide new opportunities
to interfere with the disease process particularly in cases of already
established disease.
| Footnotes |
|---|
2 Address correspondence and reprint requests to Dr. Jack Antel, Department of Neurology, Montréal Neurologic Hospital, 3801 University Street, Montréal, Québec H3A 2B4 Canada. E-mail address: ![]()
3 Abbreviations used in this paper: MS, multiple sclerosis; CNS, central nervous system; MBP, myelin basic protein; OL, oligodendrocyte; MNC, mononuclear cell; PE, phycoerythrin. ![]()
Received for publication July 16, 1997. Accepted for publication November 17, 1997.
| References |
|---|
|
|
|---|
/ß T cell receptor kill their target without self restriction. Proc. Natl. Acad. Sci. USA 86:2824.
This article has been cited by other articles:
![]() |
S.-Y. Na, H. Eujen, K. Gobel, S. G. Meuth, K. Martens, H. Wiendl, and T. Hunig Antigen-Specific Blockade of Lethal CD8 T-Cell Mediated Autoimmunity in a Mouse Model of Multiple Sclerosis J. Immunol., May 15, 2009; 182(10): 6569 - 6575. [Abstract] [Full Text] [PDF] |
||||
![]() |
M. A. Wallet, R. R. Flores, Y. Wang, Z. Yi, C. J. Kroger, C. E. Mathews, H. S. Earp, G. Matsushima, B. Wang, and R. Tisch MerTK regulates thymic selection of autoreactive T cells PNAS, March 24, 2009; 106(12): 4810 - 4815. [Abstract] [Full Text] [PDF] |
||||
![]() |
A. Saxena, J. Bauer, T. Scheikl, J. Zappulla, M. Audebert, S. Desbois, A. Waisman, H. Lassmann, R. S. Liblau, and L. T. Mars Cutting Edge: Multiple Sclerosis-Like Lesions Induced by Effector CD8 T Cells Recognizing a Sequestered Antigen on Oligodendrocytes J. Immunol., August 1, 2008; 181(3): 1617 - 1621. [Abstract] [Full Text] [PDF] |
||||
![]() |
L. T. Mars, J. Bauer, D. A. Gross, F. Bucciarelli, H. Firat, D. Hudrisier, F. Lemonnier, K. Kosmatopoulos, and R. S. Liblau CD8 T Cell Responses to Myelin Oligodendrocyte Glycoprotein-Derived Peptides in Humanized HLA-A*0201-Transgenic Mice J. Immunol., October 15, 2007; 179(8): 5090 - 5098. [Abstract] [Full Text] [PDF] |
||||
![]() |
P. Somma, G. Ristori, L. Battistini, S. Cannoni, G. Borsellino, A. Diamantini, M. Salvetti, R. Sorrentino, and M. T. Fiorillo Characterization of CD8+ T cell repertoire in identical twins discordant and concordant for multiple sclerosis J. Leukoc. Biol., March 1, 2007; 81(3): 696 - 710. [Abstract] [Full Text] [PDF] |
||||
![]() |
P. Saikali, J. P. Antel, J. Newcombe, Z. Chen, M. Freedman, M. Blain, R. Cayrol, A. Prat, J. A. Hall, and N. Arbour NKG2D-Mediated Cytotoxicity toward Oligodendrocytes Suggests a Mechanism for Tissue Injury in Multiple Sclerosis J. Neurosci., January 31, 2007; 27(5): 1220 - 1228. [Abstract] [Full Text] [PDF] |
||||
![]() |
M. Brisebois, S. P. Zehntner, J. Estrada, T. Owens, and S. Fournier A Pathogenic Role for CD8+ T Cells in a Spontaneous Model of Demyelinating Disease J. Immunol., August 15, 2006; 177(4): 2403 - 2411. [Abstract] [Full Text] [PDF] |
||||
![]() |
B. Niland, K. Banki, W. E. Biddison, and A. Perl CD8+ T Cell-Mediated HLA-A*0201-Restricted Cytotoxicity to Transaldolase Peptide 168-176 in Patients with Multiple Sclerosis J. Immunol., December 15, 2005; 175(12): 8365 - 8378. [Abstract] [Full Text] [PDF] |
||||
![]() |
A. Jurewicz, M. Matysiak, K. Tybor, L. Kilianek, C. S. Raine, and K. Selmaj Tumour necrosis factor-induced death of adult human oligodendrocytes is mediated by apoptosis inducing factor Brain, November 1, 2005; 128(11): 2675 - 2688. [Abstract] [Full Text] [PDF] |
||||
![]() |
M. A. Friese and L. Fugger Autoreactive CD8+ T cells in multiple sclerosis: a new target for therapy? Brain, August 1, 2005; 128(8): 1747 - 1763. [Abstract] [Full Text] [PDF] |
||||
![]() |
M. P. Crawford, S. X. Yan, S. B. Ortega, R. S. Mehta, R. E. Hewitt, D. A. Price, P. Stastny, D. C. Douek, R. A. Koup, M. K. Racke, et al. High prevalence of autoreactive, neuroantigen-specific CD8+ T cells in multiple sclerosis revealed by novel flow cytometric assay Blood, June 1, 2004; 103(11): 4222 - 4231. [Abstract] [Full Text] [PDF] |
||||
![]() |
Y. C. Q. Zang, S. Li, V. M. Rivera, J. Hong, R. R. Robinson, W. T. Breitbach, J. Killian, and J. Z. Zhang Increased CD8+ Cytotoxic T Cell Responses to Myelin Basic Protein in Multiple Sclerosis J. Immunol., April 15, 2004; 172(8): 5120 - 5127. [Abstract] [Full Text] [PDF] |
||||
![]() |
C. Skulina, S. Schmidt, K. Dornmair, H. Babbe, A. Roers, K. Rajewsky, H. Wekerle, R. Hohlfeld, and N. Goebels Multiple sclerosis: Brain-infiltrating CD8+ T cells persist as clonal expansions in the cerebrospinal fluid and blood PNAS, February 24, 2004; 101(8): 2428 - 2433. [Abstract] [Full Text] [PDF] |
||||
![]() |
F. Giuliani, C. G. Goodyer, J. P. Antel, and V. W. Yong Vulnerability of Human Neurons to T Cell-Mediated Cytotoxicity J. Immunol., July 1, 2003; 171(1): 368 - 379. [Abstract] [Full Text] [PDF] |
||||
![]() |
L. Battistini, L. Piccio, B. Rossi, S. Bach, S. Galgani, C. Gasperini, L. Ottoboni, D. Ciabini, M. D. Caramia, G. Bernardi, et al. CD8+ T cells from patients with acute multiple sclerosis display selective increase of adhesiveness in brain venules: a critical role for P-selectin glycoprotein ligand-1 Blood, June 15, 2003; 101(12): 4775 - 4782. [Abstract] [Full Text] [PDF] |
||||
![]() |
A. Jurewicz, M. Matysiak, K. Tybor, and K. Selmaj TNF-induced death of adult human oligodendrocytes is mediated by c-jun NH2-terminal kinase-3 Brain, June 1, 2003; 126(6): 1358 - 1370. [Abstract] [Full Text] [PDF] |
||||
![]() |
C. Gianfrani, R. Troncone, P. Mugione, E. Cosentini, M. De Pascale, C. Faruolo, S. Senger, G. Terrazzano, S. Southwood, S. Auricchio, et al. Celiac Disease Association with CD8+ T Cell Responses: Identification of a Novel Gliadin-Derived HLA-A2-Restricted Epitope J. Immunol., March 1, 2003; 170(5): 2719 - 2726. [Abstract] [Full Text] [PDF] |
||||
![]() |
M. Matysiak, A. Jurewicz, D. Jaskolski, and K. Selmaj TRAIL induces death of human oligodendrocytes isolated from adult brain Brain, November 1, 2002; 125(11): 2469 - 2480. [Abstract] [Full Text] [PDF] |
||||
![]() |
W Bruck, C Lucchinetti, and H Lassmann The pathology of primary progressive multiple sclerosis Multiple Sclerosis, April 1, 2002; 8(2): 93 - 97. [Abstract] [PDF] |
||||
![]() |
J. M. Redwine, M. J. Buchmeier, and C. F. Evans In Vivo Expression of Major Histocompatibility Complex Molecules on Oligodendrocytes and Neurons during Viral Infection Am. J. Pathol., October 1, 2001; 159(4): 1219 - 1224. [Abstract] [Full Text] |
||||
![]() |
H. Babbe, A. Roers, A. Waisman, H. Lassmann, N. Goebels, R. Hohlfeld, M. Friese, R. Schroder, M. Deckert, S. Schmidt, et al. Clonal Expansions of CD8+ T Cells Dominate the T Cell Infiltrate in Active Multiple Sclerosis Lesions as Shown by Micromanipulation and Single Cell Polymerase Chain Reaction J. Exp. Med., August 8, 2000; 192(3): 393 - 404. [Abstract] [Full Text] [PDF] |
||||
![]() |
Z. Mikloska, M. Ruckholdt, I. Ghadiminejad, H. Dunckley, M. Denis, and A. L. Cunningham Monophosphoryl Lipid A and QS21 Increase CD8 T Lymphocyte Cytotoxicity to Herpes Simplex Virus-2 Infected Cell Proteins 4 and 27 Through IFN-{gamma} and IL-12 Production J. Immunol., May 15, 2000; 164(10): 5167 - 5176. [Abstract] [Full Text] [PDF] |
||||
| |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |